Semaglutide on the NHS — UK access pathways

The three NHS doors for semaglutide

1. Type 2 diabetes — Ozempic (weekly injection). Routinely prescribed in NHS diabetes services where it fits NICE NG28 treatment criteria, typically after metformin and where there is a need for additional glycaemic control plus cardiovascular benefit. The GP or diabetes specialist makes the call.
2. Type 2 diabetes — Rybelsus (oral semaglutide, daily). Same indication as Ozempic but oral. Some NHS formularies prefer the injectable for cost / supply reasons; some patients prefer oral. Discuss with your prescriber.
3. Weight management — Wegovy (NICE TA875). Accessed through specialist weight management services (typically tier 3). Eligibility is set by NICE TA875 and local commissioning.

Wegovy NHS eligibility under NICE TA875

The published criteria for NHS Wegovy via specialist weight management services are:

• BMI ≥ 35 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease), or
• BMI ≥ 30 in defined ethnic groups (South Asian, Chinese, Black African, African-Caribbean, Middle Eastern) where lower BMI thresholds apply.

The treatment is licensed for use alongside a reduced-calorie diet and increased physical activity, and continued only while clinically appropriate. NICE TA875 covers two years of treatment in specialist services; longer-term continuation depends on local commissioning arrangements.

Ozempic NHS eligibility

Ozempic is licensed for the management of type 2 diabetes. NICE NG28 and local formularies set the prescribing position; semaglutide is generally an option after metformin (or in metformin-intolerant patients), particularly where cardiovascular risk reduction is relevant or where weight reduction would be clinically helpful. Ozempic is not licensed for weight loss alone; UK prescribers may not prescribe it off-label for weight management on the NHS.

The realistic wait picture

For diabetes access, the wait is the standard GP / diabetes service wait in your area — typically days to weeks. For weight management access (Wegovy), the wait depends on local tier-3 service capacity and is often substantial; some regions have lists of months to over a year. This is the most common reason patients turn to private prescribers; see NHS vs private GLP-1 for an honest comparison.

How to get started

1. For diabetes: book a routine GP appointment, ask about whether semaglutide (Ozempic) or oral semaglutide (Rybelsus) fits your treatment plan. Have your most recent HbA1c, cardiovascular risk score, and current medication list ready.
2. For weight management: ask your GP for a referral to your local specialist weight management service. Be prepared: your BMI, weight-related comorbidities, previous weight-loss attempts (diet, lifestyle, medication, surgery considerations) will all be reviewed.
3. Either pathway: raise any contraindications yourself — personal or family history of medullary thyroid carcinoma, MEN2, history of pancreatitis, current pregnancy or pregnancy planning.

What semaglutide NHS access does not give you

• Choice of brand. The NHS prescribes the licensed formulation that matches your indication. You don't get to ask for Ozempic if you only have a weight-management indication.
• Faster diabetes appointments than your local service offers. The medicine is licensed; the bottleneck is the clinic appointment, not the medicine.
• Lifestyle bypass. Both Wegovy and Ozempic are licensed alongside diet and activity intervention. NHS services expect engagement with that, not in addition to but as part of the treatment.

If you cannot get NHS semaglutide

The two lawful UK alternatives are: (a) wait for your NHS pathway (capacity does change as commissioning evolves), or (b) access via a GMC-registered private prescriber working with a regulated UK pharmacy — see private clinics — what good looks like and our how to check a UK pharmacy guide. Do not use social-media sellers, Telegram, or grey-market suppliers — the MHRA has issued repeated alerts on counterfeit semaglutide, including pens that contained insulin rather than semaglutide.